LAVANNYA PANDIT to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications LAVANNYA PANDIT has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.565
-
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect Dis. 2022 05; 22(5):622-635.
Score: 0.146
-
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial. Ann Intern Med. 2022 02; 175(2):234-243.
Score: 0.146
-
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. N Engl J Med. 2021 03 11; 384(10):905-914.
Score: 0.136
-
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021 01 07; 384(1):20-30.
Score: 0.136